| Schedule of Segment Profit or Loss, Including Significant Segment Expenses |
The table below provides a summary of the segment profit or loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
Year Ended
December 31, |
|
|
|
2025 |
|
|
2024 |
|
Revenues: |
|
|
|
|
|
|
License revenue - former related party |
|
$ |
— |
|
|
$ |
5,909 |
|
License revenue |
|
|
2,036 |
|
|
|
326 |
|
Total revenues |
|
|
2,036 |
|
|
|
6,235 |
|
Research and development expenses: |
|
|
|
|
|
|
Claseprubart program-related expenses: |
|
|
|
|
|
|
Clinical operation activity costs |
|
|
49,870 |
|
|
|
25,764 |
|
CMC activity costs |
|
|
16,570 |
|
|
|
19,494 |
|
Preclinical study activity costs |
|
|
3,563 |
|
|
|
8,537 |
|
Other costs |
|
|
2,069 |
|
|
|
600 |
|
Total claseprubart program-related expenses |
|
|
72,072 |
|
|
|
54,395 |
|
Discovery expenses(1) |
|
|
32,070 |
|
|
|
2,117 |
|
Personnel and related costs |
|
|
26,008 |
|
|
|
16,638 |
|
Stock-based compensation expense |
|
|
10,090 |
|
|
|
5,576 |
|
Other costs |
|
|
5,398 |
|
|
|
4,379 |
|
Total research and development expenses |
|
|
145,638 |
|
|
|
83,105 |
|
General and administrative expenses: |
|
|
|
|
|
|
Stock-based compensation expense |
|
|
12,703 |
|
|
|
7,318 |
|
Personnel and related costs |
|
|
11,531 |
|
|
|
8,249 |
|
Other costs |
|
|
10,097 |
|
|
|
9,427 |
|
Total general and administrative expenses |
|
|
34,331 |
|
|
|
24,994 |
|
Other income, net |
|
|
15,596 |
|
|
|
16,895 |
|
Net loss |
|
$ |
(162,337 |
) |
|
$ |
(84,969 |
) |
|
|
(1) |
For the year ended December 31, 2025, discovery expenses include $30.0 million related to the upfront and near-term milestone payments pursuant to the Leads License Agreement (as defined below in Note 16) related to DNTH212. Additional information is included in Note 16. |
|